EA201990565A1 - Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид - Google Patents
Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероидInfo
- Publication number
- EA201990565A1 EA201990565A1 EA201990565A EA201990565A EA201990565A1 EA 201990565 A1 EA201990565 A1 EA 201990565A1 EA 201990565 A EA201990565 A EA 201990565A EA 201990565 A EA201990565 A EA 201990565A EA 201990565 A1 EA201990565 A1 EA 201990565A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crystalline
- displaced
- pyrazolyl steroid
- steroid
- pyrazolyl
- Prior art date
Links
- VVUQRXPUVKXAIO-XFUVECHXSA-N 19-nor-5-androstenediol Chemical compound C1[C@@H](O)CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 VVUQRXPUVKXAIO-XFUVECHXSA-N 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Изобретение относится к 19-нор C3,3-дизамещенному C21-пиразолил стероиду формулы (I)и его кристаллической твердой форме и композиции. Также в настоящем документе описаны способы получения кристаллической твердой формы 19-нор C3,3-дизамещенного C21-пиразолил стероида формулы (I) и способы применения 19-нор C3,3-дизамещенного C21-пиразолил стероида формулы (I) или кристаллической твердой формы, его фармацевтически приемлемых солей и фармацевтически приемлемой композиции.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 | |
| PCT/US2017/048267 WO2018039378A1 (en) | 2016-08-23 | 2017-08-23 | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990565A1 true EA201990565A1 (ru) | 2019-07-31 |
Family
ID=59772778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990565A EA201990565A1 (ru) | 2016-08-23 | 2017-08-23 | Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11236121B2 (ru) |
| EP (2) | EP3981763A1 (ru) |
| JP (2) | JP2019524853A (ru) |
| KR (2) | KR20230079470A (ru) |
| CN (4) | CN110088091A (ru) |
| AR (3) | AR109393A1 (ru) |
| AU (3) | AU2017315682B2 (ru) |
| BR (1) | BR112019003637A2 (ru) |
| CA (1) | CA3034262A1 (ru) |
| CL (2) | CL2019000477A1 (ru) |
| CO (1) | CO2019002596A2 (ru) |
| EA (1) | EA201990565A1 (ru) |
| EC (1) | ECSP19020141A (ru) |
| IL (1) | IL302480A (ru) |
| JO (1) | JOP20190022B1 (ru) |
| MA (1) | MA46042A (ru) |
| MX (2) | MX2019002193A (ru) |
| PE (1) | PE20190915A1 (ru) |
| PH (1) | PH12019500375A1 (ru) |
| SG (1) | SG11201901445TA (ru) |
| TW (2) | TWI808945B (ru) |
| WO (1) | WO2018039378A1 (ru) |
| ZA (1) | ZA201901051B (ru) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3572417A3 (en) | 2011-10-14 | 2020-03-25 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US9512165B2 (en) | 2013-04-17 | 2016-12-06 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| PL2986624T3 (pl) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia |
| CA2918735C (en) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3035940B1 (en) | 2013-08-23 | 2018-10-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| NZ769042A (en) | 2014-10-16 | 2023-12-22 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| CN117024501A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| PT3224269T (pt) | 2014-11-27 | 2020-06-01 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios do snc |
| SI3250210T1 (sl) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN109689673B (zh) | 2016-07-11 | 2023-03-14 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| JOP20190022B1 (ar) | 2016-08-23 | 2023-03-28 | Sage Therapeutics Inc | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| TW202342058A (zh) * | 2017-09-07 | 2023-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| WO2019055764A1 (en) * | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| CN112533611A (zh) * | 2018-06-12 | 2021-03-19 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| MA54594A (fr) | 2018-12-05 | 2022-04-06 | Sage Therapeutics Inc | Stéroïdes neuroactifs et leurs procédés d'utilisation |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| CN111770915A (zh) * | 2019-01-31 | 2020-10-13 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
| WO2020242772A1 (en) | 2019-05-28 | 2020-12-03 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| BR112021024033A2 (pt) | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
| KR20220066262A (ko) * | 2019-08-07 | 2022-05-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 스테로이드 유도체 조절제의 염 및 결정형 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| US20230346801A1 (en) | 2020-03-25 | 2023-11-02 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| AR123018A1 (es) | 2020-07-20 | 2022-10-26 | Sage Therapeutics Inc | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este |
| AU2022214187A1 (en) | 2021-01-28 | 2023-07-13 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| AU2022238365A1 (en) | 2021-03-17 | 2023-09-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| EP4329769A1 (en) | 2021-04-29 | 2024-03-06 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| JP2024515829A (ja) | 2021-04-29 | 2024-04-10 | セージ セラピューティクス， インコーポレイテッド | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
| WO2023009584A1 (en) | 2021-07-28 | 2023-02-02 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
| WO2023158668A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| CA2396079A1 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| KR100960062B1 (ko) | 2002-02-08 | 2010-05-31 | 오노 야꾸힝 고교 가부시키가이샤 | 피페리딘 유도체 화합물 및 상기 화합물을 유효성분으로서 함유하는 약제 |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| EP2736919A4 (en) | 2011-07-29 | 2015-01-14 | Univ California | NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014085668A1 (en) | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| TR201808616T4 (tr) | 2012-12-18 | 2018-07-23 | Sage Therapeutics Inc | Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri. |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US9512165B2 (en) * | 2013-04-17 | 2016-12-06 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN117024501A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| NZ769042A (en) | 2014-10-16 | 2023-12-22 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| JP2018526423A (ja) | 2015-09-08 | 2018-09-13 | ビューポイント セラピューティクス， インコーポレイテッド | 眼科疾患を処置するための化合物および製剤 |
| AU2016338672A1 (en) | 2015-10-16 | 2018-04-12 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| WO2017087864A1 (en) | 2015-11-20 | 2017-05-26 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| JOP20170059B1 (ar) | 2016-03-08 | 2021-08-17 | Sage Therapeutics Inc | ستيرويدات وتركيبات نشطة عصبيًا واستخداماتها |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| CN109689673B (zh) | 2016-07-11 | 2023-03-14 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| JOP20190022B1 (ar) | 2016-08-23 | 2023-03-28 | Sage Therapeutics Inc | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| CN116370475A (zh) | 2017-08-31 | 2023-07-04 | 武田药品工业株式会社 | 中枢神经系统病症的治疗 |
| TW202342058A (zh) | 2017-09-07 | 2023-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| WO2019055764A1 (en) | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
| WO2019094724A1 (en) | 2017-11-10 | 2019-05-16 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| US20220315621A1 (en) | 2017-12-22 | 2022-10-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA51315A (fr) | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter des troubles du snc |
| TW201930269A (zh) | 2018-01-12 | 2019-08-01 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| CN112533611A (zh) | 2018-06-12 | 2021-03-19 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| AR116695A1 (es) | 2018-10-12 | 2021-06-02 | Sage Therapeutics Inc | Los neuroesteroides y sus métodos de uso |
| TW202027754A (zh) | 2018-10-19 | 2020-08-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| MA54594A (fr) | 2018-12-05 | 2022-04-06 | Sage Therapeutics Inc | Stéroïdes neuroactifs et leurs procédés d'utilisation |
| WO2020132504A1 (en) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| TW202110824A (zh) | 2019-05-24 | 2021-03-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| BR112021024033A2 (pt) | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
| JP2023504517A (ja) | 2019-12-05 | 2023-02-03 | セージ セラピューティクス， インコーポレイテッド | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| AU2021238346A1 (en) | 2020-03-18 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| US20230346801A1 (en) | 2020-03-25 | 2023-11-02 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| AR123018A1 (es) | 2020-07-20 | 2022-10-26 | Sage Therapeutics Inc | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este |
-
2017
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es unknown
- 2017-08-23 MX MX2019002193A patent/MX2019002193A/es unknown
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko not_active Application Discontinuation
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Application Discontinuation
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 TW TW112101437A patent/TW202342059A/zh unknown
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt active Search and Examination
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en active Application Filing
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US20230399357A1/en active Pending
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990565A1 (ru) | Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид | |
| MX2020004504A (es) | Derivados de fenoximetilo. | |
| PH12018500777A1 (en) | Farnesoid x receptor modulators | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
| MX2019015744A (es) | Composiciones farmaceuticas. | |
| MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| MX2021006697A (es) | Composición y método para el crecimiento del cabello. | |
| EA202091505A1 (ru) | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa | |
| MX2018003130A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA201791896A1 (ru) | Дезацетокситубулизин н и его аналоги | |
| PH12020550703A1 (en) | Sulfonamide compounds and use thereof | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| CY1125355T1 (el) | Πεντακυκλικη ενωση | |
| EP4327880A3 (en) | Solid state form of ribociclib succinate | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| WO2016166720A3 (en) | Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
| MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
| EA201690294A1 (ru) | Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов |